💊
Nintedanib Viatris
nintedanib
Idiopathische longfibrose;Interstitiële longaandoeningen;Longfibrose
✅ Geautoriseerd
Algemeen
✅
Geen actieve meldingen
Dit geneesmiddel heeft geen lopende tekorten, veiligheidsbrieven of terugroepacties.
Waarvoor het wordt gebruikt
Nintedanib Viatris is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Viatris is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Nintedanib Viatris is indicated in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs). Nintedanib Viatris is indicated in adults, adolescents and children aged 6 years and older for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD).
⚠️ Patiëntveiligheid
No
Officiële EMA-pagina
https://www.ema.europa.eu/en/medicines/human/EPAR/nintedanib-viatris